GLP-1 beyond weight loss: cardiovascular protection, kidney disease, MASH liver therapy, neurodegeneration, and addiction.Among the most unexpected developments in GLP-1 research is accumulating evidence for effects on reward circuitry and addictive behaviors.
SGLT2 inhibitors and GLP-1 receptor agonists (RAs), have transformed the management of type 2 diabetes (T2D), obesity, chronic kidney disease (CKD), and heart failure (HF). Their benefits extend well beyond glycemic control and weight loss and include cardiorenal (CR) protection.
Such details provide a deeper understanding and appreciation for Glp-1 Therapy Effects On Fibrosis In T2D.
Semaglutide reduced liver fat and improved fibrosis in a Phase III trial of people with MASH, adding to the growing list of benefits for GLP-1 agonists.
Slide 37: Tirzepatide in the context of T2DM treatment: effect on HbA1c. Given the potentially groundbreaking findings of their respective trials, the use of SGLT-2i and GLP-1RA therapy has revolutionized the treatment approach for T2D.
Side effects for GLP ones are known for everyone by now. Nausea, diarrhea, constipation, vomiting, common GI side effects with GLP-1s. It's also important to know that the pipeline is an extremely rich. The oral agents that are there running lanifibranor is not on progression.
:max_bytes(150000):strip_icc()/HDC-GettyImages-2195485788-299e147644524b339a084114355dff83.jpg "Image result for GLP-1 therapy effects on fibrosis in T2D")
